Targeting Mammalian 5-Lipoxygenase by Dietary Phenolics as an Anti-Inflammatory Mechanism: A Systematic Review

5-Lipoxygenase (5-LOX) plays a key role in inflammation through the biosynthesis of leukotrienes and other lipid mediators. Current evidence suggests that dietary (poly)phenols exert a beneficial impact on human health through anti-inflammatory activities. Their mechanisms of action have mostly been associated with the modulation of pro-inflammatory cytokines (TNF-α, IL-1β), prostaglandins (PGE2), and the interaction with NF-κB and cyclooxygenase 2 (COX-2) pathways. Much less is known about the 5-lipoxygenase (5-LOX) pathway as a target of dietary (poly)phenols. This systematic review aimed to summarize how dietary (poly)phenols target the 5-LOX pathway in preclinical and human studies. The number of studies identified is low (5, 24, and 127 human, animal, and cellular studies, respectively) compared to the thousands of studies focusing on the COX-2 pathway. Some (poly)phenolics such as caffeic acid, hydroxytyrosol, resveratrol, curcumin, nordihydroguaiaretic acid (NDGA), and quercetin have been reported to reduce the formation of 5-LOX eicosanoids in vitro. However, the in vivo evidence is inconclusive because of the low number of studies and the difficulty of attributing effects to (poly)phenols. Therefore, increasing the number of studies targeting the 5-LOX pathway would largely expand our knowledge on the anti-inflammatory mechanisms of (poly)phenols.


Lipoxygenases
Lipoxygenases (LOXs) are found widely in nature and are abundant in plants and animals. Polyunsaturated fatty acids (PUFA) containing cis double bonds are the substrates of these enzymes. Linoleic and linolenic acids (18-carbon fatty acids) and arachidonic acid (AA; 20-carbon fatty acid) are the most common substrates for LOXs in plants and animals, respectively. The nomenclature of these enzymes is based on the specific position of the carbon oxygenated. Some examples are 9-LOX and 13-LOX, which are important LOXs described in plants, whereas 5-LOX, 12-LOX, and 15-LOX are present in animals [1,2].
LOXs are involved in the modulation of essential biological functions by synthesizing specific hydroperoxides, which are further metabolized into signaling molecules/biological mediators. Among these molecules, divinyl ethers, aldehydes, and jasmonates exert protective effects in plants from abiotic stress and(or) pathogens [3,4], whereas lipoxins or leukotrienes modulate the inflammatory response in humans [5]. LOX-catalyzed reactions are also associated with undesirable effects. Legume spoilage, generation of hay-like flavor, loss of pigments (e.g., carotenoids and chlorophylls), enzymatic browning and/or

5-Lipoxygenase and Inflammation
Inflammation is a complex physiological process that functions as a network of interconnected elements regulated by many signaling molecules, including cytokines, chemokines, and lipid mediators. The disruption of the equilibrium between these molecules results in chronic inflammation and the development of related diseases [9,10]. AA is a substrate for the biosynthesis of several groups of lipid mediators collectively termed eicosanoids. The formation of prostaglandins (PGs) and LTs are two major pathways of eicosanoid biosynthesis catalyzed by cyclooxygenases (COX)-1/COX-2 and 5-lipoxygenase (5-LOX), respectively. The established role of the latter enzyme is its contribution to (patho)physiological inflammation by the formation of LTs [11,12]. The enzyme 5-LOX is also central for the biosynthesis of the more recently discovered (and less investigated) 5-LOXderived metabolites termed hemiketal (HK) eicosanoids [13] that appear to be novel lipid mediators in inflammation. LTs, at low nanomolar concentrations, can modulate the immune response and promote chronic inflammation, implying a role of these eicosanoids in a range of inflammatory diseases, including atherosclerosis, inflammatory bowel diseases, rheumatoid arthritis, and asthma [14,15]. The understanding of the biology of 5-LOX and its LT products has culminated in the development of anti-LT drugs (receptor antagonist and enzyme inhibitors) that are used clinically in the treatment of asthma and that may also provide a clinical benefit in atherosclerosis [11,16,17]. However, although these drugs show therapeutic effects (e.g., against asthma and atherosclerosis), the side-effects associated with their use and/or the poor in vivo efficacy highlight the need for better therapeutic options, including the search for possible alternatives such as natural products that may include dietary (poly)phenolic compounds.
In this regard, dietary (poly)phenols have been tested in numerous preclinical (animal and cellular) models and in a limited number of human studies, showing anti-inflammatory effects by diverse mechanisms of action, including cytokine modulation, inhibition of inducible nitric oxide synthase (iNOS) and nuclear factor kappa B (NF-κB) activation, as well as decreasing PG production by down-regulation of COX-2 [18,19]. Much less is known about the anti-inflammatory effect of (poly)phenols targeting the 5-LOX pathway. It is noteworthy that the number of studies that have investigated the anti-inflammatory effects of dietary (poly)phenols on 5-LOX (around 120 hits for a PubMed search) is much lower compared to COX-2 (around 2500 studies). The preponderance of a focus on the COX-2 pathway is difficult to rationalize given the importance of targeting both COX-2 and 5-LOX pathways to ameliorate undesirable effects of chronic inflammation.
Accordingly, our main objective was to perform a systematic and critical review of the current evidence concerning the anti-inflammatory effect of dietary (poly)phenolics via modulation of the 5-LOX pathway to identify knowledge gaps and future research needs, allowing an increase in the understanding of the anti-inflammatory effects of (poly)phenols.

Biosynthesis of 5-LOX-Derived Eicosanoids
Early studies on LT biosynthesis date back to the 1970s when Samuelsson and Borgeat described the formation of 5S-hydroxyeicosatetraenoic acid (5S-HETE) together with new arachidonate metabolites that were later termed LTA 4 and LTB 4 in peripheral leukocytes [20,21]. These investigations established a novel pathway of oxidative transformation of AA catalyzed by 5-LOX.
5-LOX is a key enzyme in the biosynthesis of LTs from AA ( Figure 1). The formation of LTs requires activation of phospholipase A 2 (PLA 2 ) by Ca +2 -dependent (such as purinergic stimulation by ATP) or independent (i.e., innate immune "toll-like" receptor (TLR) stimulation by LPS) mechanisms, resulting in the hydrolysis of AA esterified in the membrane phospholipids [22,23]. In intact cells, 5-LOX is activated in response to Ca +2 influx and associates with 5-lipoxygenase activating protein (FLAP) to form a 5-LOX/FLAP complex at the nuclear membrane. In this complex, the essential function of FLAP is to present AA as a substrate to 5-LOX. The 5-LOX catalytic reaction involves an initial hydrogen abstraction from carbon 7 of AA and the addition of molecular oxygen to produce 5S-hydroperoxyeicosatetraenoic acid (5S-HPETE) followed by a second hydrogen abstraction from position 10 to form LTA 4 . LTA 4 is unstable and undergoes enzymatic transformation by LTA 4 hydrolase to form LTB 4 or conjugation with glutathione by LTC 4 synthase to produce LTC 4 , which is further metabolized by γ-glutamyltransferase and dipeptidase yielding LTD 4 and LTE 4 , respectively [24,25]. Alternatively, 5S-HPETE can undergo reduction to 5S-HETE, which is in turn oxidized by 5-hydroxyeicosanoid dehydrogenase (5-HEDH), yielding 5-oxo-eicosatetraenoic acid (5-oxo-ETE) [26] (Figure 1).

Transcellular Biosynthesis of Leukotrienes and Lipoxins
LT biosynthesis goes beyond a string of enzymatic transformations in single cells (i.e., granulocytes and mast cells). Namely, LT biosynthesis involves transcellular biosynthesis, a term that describes eicosanoid formation by cell-cell interactions [27]. Early evidence on transcellular biosynthesis of LTs came from in vitro studies describing LTA 4 exchange between neutrophils and erythrocytes or endothelial cells to produce LTB 4 or LTC 4 , respectively [28,29]. Subsequent in vivo studies provided evidence that transcellular biosynthesis of LTB 4 and LTC 4 does indeed occur in animal models [30,31].

Transcellular Biosynthesis of Leukotrienes and Lipoxins
LT biosynthesis goes beyond a string of enzymatic transformations in single cells (i.e., granulocytes and mast cells). Namely, LT biosynthesis involves transcellular biosynthesis, a term that describes eicosanoid formation by cell-cell interactions [27]. Early evidence on transcellular biosynthesis of LTs came from in vitro studies describing LTA4 exchange between neutrophils and erythrocytes or endothelial cells to produce LTB4 or LTC4, respectively [28,29]. Subsequent in vivo studies provided evidence that transcellular biosynthesis of LTB4 and LTC4 does indeed occur in animal models [30,31]. mation of AA to 15S-HPETE followed by the conversion by 5-LOX to yield LXA4 and LXB4 [35]. The synthesis of LXs is not limited to the interaction of only lipoxygenases. Acetylated COX-2 retains catalytic activity, forming 15R-HETE as the primary product [36,37], which can serve as a substrate for 5-LOX producing the aspirin-triggered LXs (LXA4 and LXB4 epimers) known as 15-epi-LXA4 and 15-epi-LXB4 [22,38,39]. LXs and aspirin-triggered LXs have anti-inflammatory properties promoting the resolution of inflammation [40][41][42], which contrasts with the largely pro-inflammatory effects of other products of the 5-LOX pathway. Besides a role in the biosynthesis of LTs and LXs, 5-LOX is also a key enzyme in the biosynthesis of a novel type of eicosanoids recently described. In vitro biochemical studies showed that COX-2 catalyzes the oxidation of the 5-LOX product 5S-HETE (resulting from the reduction of 5S-HPETE) to form a di-endoperoxide [43] and 5-OH-PGH2 [44], which are equivalent to the prostaglandin endoperoxide PGH2 of the COX-2 pathway. The reaction also yields two minor compounds identified as 5,11-and 5,15-di-HETE, the 5-hydroxy-analogs of the known COX by-products, 11-and 15-HETE [45,46]. Additional stud- Besides a role in the biosynthesis of LTs and LXs, 5-LOX is also a key enzyme in the biosynthesis of a novel type of eicosanoids recently described. In vitro biochemical studies showed that COX-2 catalyzes the oxidation of the 5-LOX product 5S-HETE (resulting from the reduction of 5S-HPETE) to form a di-endoperoxide [43] and 5-OH-PGH 2 [44], which are equivalent to the prostaglandin endoperoxide PGH 2 of the COX-2 pathway. The reaction also yields two minor compounds identified as 5,11-and 5,15-di-HETE, the 5-hydroxy-analogs of the known COX by-products, 11-and 15-HETE [45,46]. Additional studies of the 5-LOX/COX-2 crossover pathways described the in vitro transformation (enzymatic and non-enzymatic) of the di-endoperoxide to two hemiketals (HKs) named HKE 2 and HKD 2 [13] and of 5-OH-PGH 2 to 5-OH-PGE 2 and 5-OH-PGD 2 [44] as shown in Figure 3.
Biosynthesis of HKE 2 and HKD 2 was established using an ex vivo model of human isolated leukocytes, stimulated with calcium ionophore A23187 and LPS for 5-LOX activation and COX-2 up-regulation, respectively [13]. Analysis of the time-course of the formation of HKs in human leukocyte mixtures revealed that their biosynthesis mainly depends on the availability of the 5S-HETE substrate and, to a lesser extent, on the activity of COX-2 [47]. HK formation in the mixture of human leukocytes may be another example of transcellular biosynthesis, given that a single type of leukocyte is unlikely to exhibit a significant activity of both 5-LOX and COX-2. The dependence of HK biosynthesis on the activation of leukocyte mixtures by both A23187 (inducing 5-LOX) and LPS (inducing COX-2) suggests a role for neutrophils and activated monocytes/macrophages, respectively, although this was not directly established ( Figure 4). ies of the 5-LOX/COX-2 crossover pathways described the in vitro transformation (enzymatic and non-enzymatic) of the di-endoperoxide to two hemiketals (HKs) named HKE2 and HKD2 [13] and of 5-OH-PGH2 to 5-OH-PGE2 and 5-OH-PGD2 [44] as shown in Figure  3. Biosynthesis of HKE2 and HKD2 was established using an ex vivo model of human isolated leukocytes, stimulated with calcium ionophore A23187 and LPS for 5-LOX activation and COX-2 up-regulation, respectively [13]. Analysis of the time-course of the formation of HKs in human leukocyte mixtures revealed that their biosynthesis mainly depends on the availability of the 5S-HETE substrate and, to a lesser extent, on the activity of COX-2 [47]. HK formation in the mixture of human leukocytes may be another example of transcellular biosynthesis, given that a single type of leukocyte is unlikely to exhibit a

Role of 5-Lipoxygenase-Derived Eicosanoids in Inflammation
Decades of intense investigation have identified LTs as potent inducers of inflammation through the interaction with distinct G protein-coupled receptors. LTB 4 was one of the first chemotactic molecules identified [48] and is a well-known pro-inflammatory molecule that exerts its effects through interaction with its high-affinity receptor BLT1 [49,50]. LTB 4 also binds (and activates) a second receptor, BLT2, albeit with much less affinity than that reported for BLT1, and its function via interaction with BLT2 remains elusive [51]. Thus, LTB 4 promotes pro-inflammatory responses such as leukocyte chemoattraction, leukocyte-endothelial cell interaction, and the release of inflammatory mediators at inflammation sites [52]. Here, aberrant inflammation results in tissue damage and impairs adequate function of host innate immune effectors such as neutrophils and activated monocytes/macrophages to recognize, respond, and resolve inflammatory processes properly.

Role of 5-Lipoxygenase-Derived Eicosanoids in Inflammation
Decades of intense investigation have identified LTs as potent inducers of inflammation through the interaction with distinct G protein-coupled receptors. LTB4 was one of the first chemotactic molecules identified [48] and is a well-known pro-inflammatory molecule that exerts its effects through interaction with its high-affinity receptor BLT1 [49,50]. LTB4 also binds (and activates) a second receptor, BLT2, albeit with much less affinity than that reported for BLT1, and its function via interaction with BLT2 remains elusive [51]. Thus, LTB4 promotes pro-inflammatory responses such as leukocyte chemoattraction, leukocyte-endothelial cell interaction, and the release of inflammatory mediators at inflammation sites [52]. Here, aberrant inflammation results in tissue damage and impairs adequate function of host innate immune effectors such as neutrophils and activated monocytes/macrophages to recognize, respond, and resolve inflammatory processes properly. This dysregulated response is implicated in the pathogenesis of chronic diseases such as atherosclerosis, cardiovascular, and inflammatory bowel diseases [15,[53][54][55]. On the other hand, the cysteinyl-LTs (cysLTs), LTC4, LTD4, and LTE4 activate their cognate receptors, CysLT1 and CysLT2, and exert profound effects on airway inflammation leading to bronchoconstriction, vascular permeability, and neutrophil extravasation [6,15,[56][57][58][59].
The recently described biochemical and chemical synthesis of HKs [63,64] enables investigating the biological role(s) of these newly discovered eicosanoids. An established activity of these molecules is the stimulation of endothelial cell migration and tubulogenesis [13] and the modulation of platelet aggregation [63], implying a possible role in atherosclerosis and CVD. However, unlike LTs, it remains unexplored thus far whether HKE2 and HKD2 exert their effects via interaction with a specific receptor ( Figure 5). Even less is known about the biological activity of 5-OH-PGs that appear not to activate traditional prostanoid receptors [44]. 5-HETE is a particular eicosanoid that shows limited biological activity by itself but serves as a precursor to form biologically active molecules, including 5-oxo-ETE, HKs, and 5-OH-PGs. 5-oxo-ETE is an oxidized metabolite of 5S-HETE that binds to the 5-oxo-ETE receptor (OXE), exerting a powerful granulocyte chemoattractant effect [60][61][62].
The recently described biochemical and chemical synthesis of HKs [63,64] enables investigating the biological role(s) of these newly discovered eicosanoids. An established activity of these molecules is the stimulation of endothelial cell migration and tubulogenesis [13] and the modulation of platelet aggregation [63], implying a possible role in atherosclerosis and CVD. However, unlike LTs, it remains unexplored thus far whether HKE 2 and HKD 2 exert their effects via interaction with a specific receptor ( Figure 5). Even less is known about the biological activity of 5-OH-PGs that appear not to activate traditional prostanoid receptors [44].

Inflammation as a Target of Dietary (Poly)phenols: Role of Their Bioavailability
Evidence from epidemiological and observational studies highlight diet as one of the cornerstones in preventing inflammatory diseases such as intestinal inflammation and cardiovascular diseases. Dietary patterns that include a high intake of fruits and vegetables, such as the Mediterranean diet as a source of high levels of phytochemicals, including dietary (poly)phenols, have been shown to significantly ameliorate inflammation [65][66][67]. In this regard, some clinical trials have provided evidence supporting the beneficial role of dietary (poly)phenols against chronic inflammatory diseases [68,69]. However, while numerous preclinical studies describe the anti-inflammatory effects of many (poly)phenolic compounds through the modulation of a plethora of cellular processes related to inflammation, the evidence of activity in humans remains unclear overall from a nutritional point of view, partly owing to the limited bioavailability of (poly)phenols [18,70]

Inflammation as a Target of Dietary (Poly)phenols: Role of Their Bioavailability
Evidence from epidemiological and observational studies highlight diet as one of the cornerstones in preventing inflammatory diseases such as intestinal inflammation and cardiovascular diseases. Dietary patterns that include a high intake of fruits and vegetables, such as the Mediterranean diet as a source of high levels of phytochemicals, including dietary (poly)phenols, have been shown to significantly ameliorate inflammation [65][66][67]. In this regard, some clinical trials have provided evidence supporting the beneficial role of dietary (poly)phenols against chronic inflammatory diseases [68,69]. However, while numerous preclinical studies describe the anti-inflammatory effects of many (poly)phenolic compounds through the modulation of a plethora of cellular processes related to inflammation, the evidence of activity in humans remains unclear overall from a nutritional point of view, partly owing to the limited bioavailability of (poly)phenols [18,70].
The bioavailability of dietary (poly)phenols is essential for a better understanding of the anti-inflammatory effects of (poly)phenolic compounds and to design physiologically relevant studies to corroborate their potential effects. Plant-derived foods (e.g., Citrus fruits, walnuts, pomegranates, green tea, soy, grapes, and others) contain phenolic compounds in free form or conjugated with sugar moieties, which are not well absorbed in the small intestine, thus limiting their distribution in systemic tissues in their native form. Upon consumption, (poly)phenols reach the gastrointestinal tract in their original molecular form, mainly as glycosides and complex oligomeric structures, and are hydrolyzed The bioavailability of dietary (poly)phenols is essential for a better understanding of the anti-inflammatory effects of (poly)phenolic compounds and to design physiologically relevant studies to corroborate their potential effects. Plant-derived foods (e.g., Citrus fruits, walnuts, pomegranates, green tea, soy, grapes, and others) contain phenolic compounds in free form or conjugated with sugar moieties, which are not well absorbed in the small intestine, thus limiting their distribution in systemic tissues in their native form. Upon consumption, (poly)phenols reach the gastrointestinal tract in their original molecular form, mainly as glycosides and complex oligomeric structures, and are hydrolyzed and further metabolized by either intestinal enzymes or by the gut microbiota forming new metabolites [71,72]. For instance, ellagitannins (ETs) (such as punicalagin from pomegranate) and their hydrolysis product ellagic acid (EA) undergo gut microbiota metabolism to yield metabolites collectively termed urolithins (Uro), with the most relevant ones identified as Uro-C, Uro-A, IsoUro-A, and Uro-B. Similarly, isoflavones (IsoFlv) and their aglycones (e.g., daidzin and daidzein, respectively) also undergo microbial metabolism producing equol and(or) O-desmethyl-angolensin (ODMA) [71,73]. The flavonoid glycoside rutin (quercetin-3-rutinoside) acts as a precursor (via deglycosylation) of quercetin in the colon [74], whereas curcumin and flavanones (such as the glycoside hesperidin and its aglycone hesperetin) can be detected in the colon for hours in their original form [75,76]. Upon absorption, the (poly)phenolic compounds and the microbial metabolites undergo phase-II metabolism to form conjugated molecules (glucuronides, sulfates, and methyl esters), which are the main molecules detected in the bloodstream, intestinal tissues, bile, feces, urine, and different systemic tissues [77,78]. Animal and human metabolism and bioavailability studies have reported that, at the intestinal level, the parental phenolic compounds (which serve as substrates of the gut microbiota) and their microbial-derived metabolites can achieve concentrations from µM to mM. In contrast, the concentrations reached in the bloodstream by the phase-II metabolites can range from nM to low µM, show anti-inflammatory effects and persist in the circulation for a few days after intake [79]. Among the phase-II metabolites detected in vivo, glucuronides are recognized as the major conjugated molecules, including Uro-A glucuronide (Uro-A glur), Quercetin-3 glur, and curcumin-glur [80][81][82]. Interestingly, the increasing knowledge about the metabolism of these compounds indicates that, under inflammatory conditions, the circulating glucuronides might also play a role as precursors of their aglycones, including luteolin [83,84], quercetin [85][86][87][88][89], resveratrol [90], Uro-A [91], and curcumin [82]. Besides, a recent trial showed that the intake of a (poly)phenolic cocktail by breast cancer patients allowed detecting relevant concentrations of free curcumin, most likely due to a conjugation-saturation process, in malignant mammary tumors [77].

Search Strategy and Study Selection
This review was conducted and reported following the Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) [92]. A comprehensive literature search was performed using PubMed and Scopus databases. The search strategy included the combination of the following search terms in abstracts and titles and was adapted for each database: (5-lipoxygenase or 5-LOX) and (phenol* or flavonoid* or polyphenol* or curcumin or resveratrol or EGCG or urolithin or procyanidin or proanthocyanidin or flavan* or flavone* or catechin or epicatechin or quercetin or curcumin or valerolactone or punicalagin or ellagic or tannin or lignan or isoflavone or equol or silymarin or thistle). Independent literature searches and article selection were completed from January to April 2021 by the authors. The authors also hand-searched the bibliography of identified articles.
Regarding eligibility criteria and study selection, all human, animal, and cellular model studies that investigated the role of 5-LOX in the anti-inflammatory effect of (poly)phenolic compounds were included in this review. Otherwise, enzymatic, in silico and in vitro studies that used physiologically unrealistic conditions, such as high concentrations (compared to those reported in vivo), irrelevant metabolic forms of (poly)phenols, inappropriate cellular models, and those conducted with plant extracts were excluded.
A total of 1250 articles were found after the literature search in the two electronic databases. Removing duplicates and full screening yielded 872 articles, of which 5 human, 24 animal, and 127 in vitro cell model studies met the inclusion criteria for this systematic review. A summary of the selection of articles included in this study is outlined in Figure 6.
The selected studies are reviewed in detail in the following sections and are summarized in independent tables (Tables 1 and 2 and Table S1) to show the current evidence of the role of 5-LOX as a target of the anti-inflammatory effects of (poly)phenols. The selected studies are reviewed in detail in the following sections and are summarized in independent tables (Tables 1 and 2 and Table S1) to show the current evidence of the role of 5-LOX as a target of the anti-inflammatory effects of (poly)phenols.

Human Studies
Targeting 5-LOX to address inflammation using a nutritional approach has been tested in only a few human studies. Only five studies determined the level of 5-LOX-derived metabolites in subjects who consumed plant-derived foodstuff (Table 1). These studies are characterized by a small number of subjects (n = 10-18) and short-term duration (up to four weeks). Four investigations using healthy volunteers described the modulation of 5-LOX expression and its metabolites (LTs and lipoxins) after the consumption of soy milk, procyanidin-enriched chocolate bars, enriched beverages, or olive oil (Table 1). One human study evaluated the effect of a diet supplemented with soy isoflavone tablets in patients with asthma. Lung function parameters remained unaltered, while isolated eosinophils showed an attenuated capacity to synthesize LTB4 ex vivo after stimulation [93]. The absence of a noticeable effect of (possible) modulation of LTs by polyphenolics in healthy subjects can be somewhat predicted and is in accord with 5-LOX-deficient animals, which are largely normal in the absence of an inflammatory stimulus [49]. Therefore, an insufficient number of human studies, mostly conducted in healthy subjects, makes it

Human Studies
Targeting 5-LOX to address inflammation using a nutritional approach has been tested in only a few human studies. Only five studies determined the level of 5-LOX-derived metabolites in subjects who consumed plant-derived foodstuff (Table 1). These studies are characterized by a small number of subjects (n = 10-18) and short-term duration (up to four weeks). Four investigations using healthy volunteers described the modulation of 5-LOX expression and its metabolites (LTs and lipoxins) after the consumption of soy milk, procyanidin-enriched chocolate bars, enriched beverages, or olive oil (Table 1). One human study evaluated the effect of a diet supplemented with soy isoflavone tablets in patients with asthma. Lung function parameters remained unaltered, while isolated eosinophils showed an attenuated capacity to synthesize LTB 4 ex vivo after stimulation [93]. The absence of a noticeable effect of (possible) modulation of LTs by polyphenolics in healthy subjects can be somewhat predicted and is in accord with 5-LOX-deficient animals, which are largely normal in the absence of an inflammatory stimulus [49]. Therefore, an insufficient number of human studies, mostly conducted in healthy subjects, makes it difficult to draw conclusions or even speculate regarding the beneficial effects of dietary phenolics via modulation of the 5-LOX pathway in humans. Table 1. Human studies describing the effects of the consumption of (poly)phenols on 5-LOX and its products.

Population of Study
Design of the Study Foodstuff; Intake and Duration Main Outcomes Ref.
↑Epicatechin plasma level (especially the high procyanidins consumer group). ↓CysLTs/PGI 2 ratio (relative to the effects observed in the low procyanidins consumer group). [94] Patients suffering mild/moderate persistent asthma (n = 13; 18-65 years)  Table 2 summarizes animal studies that considered 5-LOX (together with other markers) a potential target of plant extracts and phenolic compounds administered through the diet.

Animal Studies
Overall, a common anti-inflammatory effect observed in animals fed diets enriched with distinct plant extracts was the reduction of the carrageenan-induced paw edema volume as a prototypical assay to determine anti-inflammatory activity in vivo. Further exploration of the underlying molecular mechanisms showed inhibition of 5-LOX and COX-2 activities, lower LTB 4 and PGE 2 levels, and modulation of related inflammatory markers. Studies using animal models of arthritis described positive effects by ethanolic extracts of Jasminum laceolarium, Vitex negundo, Dendropanax dentiger, and Pterospermun heterophyllum [98][99][100][101] linked to the modulation of 5-LOX and COX-2 expression in PBMCs. However, it is unclear what compound(s) were responsible for the benefits described since crude extracts were used and the composition of the extracts was unexplored.
The consumption of diets supplemented with phenolic compounds (single or mixtures) showed beneficial anti-inflammatory effects via modulation of the 5-LOX pathway. Among the phenolic compounds, curcumin inhibited 5-LOX activity in PMNLs and reduced LTC 4 biosynthesis in paw edema (alone or combined with capsaicin) and in animal models of anaphylaxis [102,103]. Caffeic acid ameliorated brain and liver damage via downregulation of 5-LOX mRNA expression and protein level [104,105]. Flavocoxid, a dual inhibitor of 5-LOX and COX-2, targeted 5-LOX at the intestinal level, reducing LTB 4 levels and MPO activity (exerted by neutrophils) in colitis animal models [106]. As shown in Table 2, other phenolics such as catechins, quercetin, salidroside, nordihydroguaiaretic acid (NDGA), sesamol, and sesamin alleviated induced inflammation through similar molecular mechanisms, including 5-LOX-mediated inflammation.
Curcumin, capsaicin, and a mix of curcumin/capsaicin.
↓5-LOX mRNA expression in the cortical brain (at 10 and 30 mg/kg) and protein expression in hippocampi (only at 30 mg/kg); improvement of memory and learning functions together with ↓MDA, ↓ChAT, and ↓amyloid β and amyloid precursor protein. [105] ♂Wistar rats; carrageenan-induced paw edema.
↓5-LOX, 12-LOX, COX, activity in rabbit mononuclear cells; ↓CRP in plasma, ↓MPO activity in the aorta, and improvement of lipid profile and histopathological aortic features.
↓5-LOX protein expression in the liver (no effect on COX-2); ↓TNF-α, IL-1β, IL-6, MDA and ↑SOD in the liver; improvement of histopathological features; modulation of the alteration of hepatic enzymes; [104] Blood-and peritoneal-isolated leukocytes are a widely employed cellular model, allowing to determine whether the phenolic compounds exert dual inhibition on 5-LOX and COX-2. In general, some phenolic compounds such as curcumin, resveratrol, and caffeic acid show the capacity to attenuate the biosynthesis of 5-LOX (5-HETE, LTB 4 , Cys-LTs) and COX-2 (PGE 2 ) metabolites in stimulated leukocytes (Table S1). As shown in Table S1, different molecular mechanisms account for how phenolic compounds modulate the biosynthesis of eicosanoids. One of these mechanisms involves the interaction with the upstream regulator cPLA 2 . This interaction can include lower levels of cPLA 2 (i.e., through down-regulation of mRNA expression), reduced activation (phosphorylation) or translocation, and inhibition of its enzymatic activity. Further mechanisms of action are related to the inhibition of 5-LOX translocation to the nuclear membrane where it becomes active, down-regulation of 5-LOX (and COX-2) mRNA and protein expression, as well as inhibition of 5-LOX (and COX-2) enzymatic activity (Table S1). Despite valuable results gained from these studies, other aspects of how phenolic compounds modulate the 5-LOX pathway are still unclear. For example, information on the interaction of phenolic compounds with (other) essential components of the 5-LOX pathway is scarce. None of the studies included in Table S1 tested whether the phenolic compounds target LT receptors (i.e., BLT1 and BLT2), FLAP, and/or LTC 4 hydrolase. Regarding LTA 4 hydrolase, only one study showed that isoflavones failed to inhibit (or promote) its enzymatic activity [143]. Thus, the characterization of the interaction of phenolic compounds with these elements will be essential in future studies.
A common facet to the majority of in vitro studies (Table S1) is the treatment of leukocytes with glycosides and/or aglycones using conceivable concentrations at the intestinal level. Such conditions indicate that the effects observed on eicosanoid biosynthesis might be relevant in the context of intestinal inflammation [151]. These studies focused on describing the effects on leukocytes, thus overlooking the crucial role of other cells (i.e., intestinal cells). To date, a limited number of studies have investigated the interaction between dietary phenolics and the 5-LOX and COX-2 pathways in intestinal cells. In this regard, NDGA and geraniin (at 10 µM) decreased the synthesis of 5-HETE in stimulated AGS cells [152], whereas methoxy flavonoids isolated from Chiliadenus montanus failed to modulate the expression of 5-LOX in Caco-2 cells [153]. The effects of curcumin and tetrahydrocurcumin (THC) on HT-29 colon cancer cells were related to lower AA levels associated with cPLA2 inhibition; yet, how this affected the 5-LOX (or COX-2) pathway was not determined [145].
To date, no studies describe the in vitro effect of phenolic compounds or derived metabolites on lipoxin biosynthesis. Only two studies have investigated the effect of phenolics on the 5-LOX/COX-2 crossover pathway and found that curcumin and urolithins (Uro-A, IsoUro-A, and Uro-C) showed the capacity to inhibit HKE 2 and HKD 2 formation in a mixture of stimulated leukocytes [47,155]. This limited evidence underscores the need for future studies on the biosynthesis of complex 5-LOX dependent eicosanoids using isolated cell preparation or co-incubations (i.e., platelets with neutrophils) in the presence of phenolic compounds.

Conclusions
This systematic review focuses on the effect of phenolic compounds on the 5-LOX pathway. The current evidence linking modulation of the 5-LOX pathway and the antiinflammatory effects of phenolic compounds is still weak. One of the main reasons comes from the low number of human studies and clinical trials, which are essential to test the preventive and/or therapeutic effects of phenolic compounds. Thus, well-designed and robust clinical trials in patients suffering from 5-LOX-related inflammatory diseases (e.g., asthma) would be desirable. The number of animal studies is also small and more research is needed using equivalent conditions to those reported in humans, including adequate exposure times and doses of phenolic-rich foodstuff.
As expected, a higher number of in vitro studies describe the anti-inflammatory effects of phenolic compounds targeting the 5-LOX pathway. The in vitro studies focus on using mixtures of leukocytes or individual cells such as neutrophils, eosinophils, basophils, and/or mast cells. New studies should consider enlarging the range of 5-LOX-expressing cells such as dendritic cells and should consider the interaction with other cell lines such as endothelial (i.e., atherosclerosis) or intestinal cells and microbiota (i.e., intestinal inflammation). The specific role of immune-related receptors regarding the modulation of the 5-LOX pathway by phenolic compounds is an additional mechanism (not considered hitherto) that deserves attention, such as the direct effect of phenolic compounds on LT receptors or via modulation of TLR-4, which regulates CysLT1 expression in dendritic cells [156]. These studies should avoid the use of unreasonable concentrations and metabolic forms of phenolic compounds (considering metabolism and bioavailability) since this inadequate design limits the physiological significance (from an in vivo point of view) of these investigations. Hence, the design of future in vitro studies should follow the roadmap set elsewhere [157] to provide physiologically relevant results.
Another key point to contemplate is 5-LOX/COX-2 dual inhibition. Targeting the 5-LOX pathway might lead to undesirable side effects due to AA shunting towards proinflammatory COX-2-derived metabolites. Therefore, identifying and studying the biological activity of phenolic compounds that act as dual inhibitors is critical to avoid single inhibition and resulting side effects. Otherwise, a possible drawback of this approach is the reduced biosynthesis of anti-inflammatory eicosanoids due to blocking cyclooxygenases and lipoxygenases (including 5-LOX). Whether the phenolic compounds can exert antiinflammatory effects by increasing the synthesis of lipoxins is a question not addressed by the available preclinical studies. The expanded analysis of pro-and anti-inflammatory eicosanoids in future studies will improve the understanding of how phenolic compounds modulate the inflammatory response through the 5-LOX pathway.

Conflicts of Interest:
The authors declare no conflict of interest.